Mirodenafil

Mirodenafil (SK3530) is a potent, selective, and reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) belonging to the pyrrolopyrimidinone structural class. Developed by SK Chemicals Life Science (Seongnam, South Korea) and approved in 2007 by the Korea Ministry of Food and Drug Safety for the treatment of erectile dysfunction, mirodenafil is marketed as Mvix in 50 mg and 100 mg oral tablet formulations and as a 50 mg orally dissolving film. The compound inhibits PDE5 with an IC50 of 0.34 nmol/L, approximately 10-fold more potent than sildenafil (IC50 3.5 nmol/L), and exhibits selectivity ratios of approximately 48,235-fold over PDE1, 254,000-fold over PDE3, and greater than 10,000-fold over PDE11. The PDE6 selectivity ratio is approximately 30-fold, intermediate between sildenafil and tadalafil but clinically associated with a low incidence of visual disturbance at therapeutic doses. Pharmacokinetically, mirodenafil is rapidly absorbed after oral administration with a time to maximum plasma concentration of 0.67 to 1.5 hours, an elimination half-life of 1.32 to 3.0 hours, oral bioavailability of 24 to 43 percent for the parent compound, and approximately 97 percent plasma protein binding. Metabolism is predominantly hepatic through CYP3A4-mediated N-dealkylation to the active metabolite SK-3541, which retains approximately one-tenth of the PDE5 inhibitory activity of the parent compound. Clinical efficacy in erectile dysfunction has been demonstrated in multiple randomized, double-blind, placebo-controlled trials totaling more than 700 patients across general, diabetic, and hypertensive populations, with improvements in the International Index of Erectile Function erectile function domain score of 7 to 12 points over placebo. Adverse events are predominantly mild to moderate, with flushing (3.3 to 24.1 percent) and headache (1.8 to 14.8 percent) as the most common; no visual disturbances or myalgia have been reported in published trials. Beyond erectile dysfunction, mirodenafil (designated AR1001 by licensee AriBio) has entered clinical development for Alzheimer's disease on the basis of preclinical evidence demonstrating multimodal neuroprotective activity: activation of the cGMP/PKG/CREB signaling pathway, enhancement of autophagy-lysosome clearance of amyloid-beta and phosphorylated tau, suppression of neuroinflammation, and improvement of mitochondrial function. A Phase 2 randomized placebo-controlled trial in 210 patients with mild to moderate Alzheimer's disease reported that AR1001 30 mg daily as monotherapy produced a statistically significant 4.019-point improvement on the ADAS-Cog 13 at 26 weeks (p = 0.012) with concurrent reductions in plasma phosphorylated tau-181 and tau-217 biomarkers. The global Phase 3 POLARIS-AD trial, enrolling approximately 1,150 participants with early Alzheimer's disease across 200 sites under FDA, EMA, and MHRA authorization, is currently underway with a primary endpoint of change in Clinical Dementia Rating Sum of Boxes at 52 weeks. This monograph reviews the chemistry, pharmacology, pharmacokinetics, clinical evidence, sourcing, handling, stack interactions, safety profile, and comparative positioning of mirodenafil against five PDE5 inhibitor alternatives.